UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 28, 2023

BioSig Technologies, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-38659**	**26-4333375**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

55 Greens Farms Road, 1st Floor	
Westport, Connecticut	**06880**
(Address of principal executive offices)	(Zip Code)

(203) 409-5444
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of exchange on which registered**
Common Stock, par value $0.001 per share	BSGM	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

BioSig Technologies, Inc. (the "***Company***") intends, from time to time, to present, utilize, and/or distribute to the investment community and utilize at various industry and other conferences, a slide presentation and corporate summary, which are attached hereto as Exhibits 99.1 and 99.2, respectively. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibits 99.1 and 99.2.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Corporate Presentation dated April 2023 (furnished herewith pursuant to Item 7.01)
99.2	Corporate Summary dated April 2023 (furnished herewith pursuant to Item 7.01)
104	Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSIG TECHNOLOGIES, INC.

Date: April 28, 2023

By: /s/ Kenneth L. Londoner
Name: Kenneth L. Londoner
Title: Executive Chairman

Corporate Presentation

Nasdaq: BSGM

BioSig forward-looking statements

This presentation contains forward-looking statements including statements that address activities, events, or developments that BioSig expects, believes, or anticipates will or may occur in the future, such as predictions of financial performance, approvals, and launches by BioSig of new products, market acceptance of BioSig's products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig's experience and perception of current conditions, trends, expected future developments, and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig's control.

These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig's products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig's ability to effectively react to other risks and uncertainties described from time to time in BioSig's SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions, and share price volatility.

BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Reimagining what's possible in cardiac care



We are a medical technology company focused on deciphering the body's electrical signals, starting with heart rhythms.

By leveraging a first-of-its-kind combination of hardware and software, our technology delivers unprecedented cardiac signal clarity, ending the reliance on *mixed signals* and *reading between the lines*.

Growing into an expanding global market

$1.6B

Total global addressable market

14.4 million Americans suffer from cardiac arrhythmias

Atrial Fibrillation is the most common arrhythmia affecting:

~ 6.1 million people in the U.S. and growing

~ 33.5 million people worldwide

Catheter ablation is fast becoming a first-line therapy

Global ablation procedures:

~1.5 million in 2022
~8.4% CAGR

Complex ablation procedures:

~13.5% projected CAGR

EP labs are growing to meet demand

Estimated:

3,425 EP labs in U.S.

3,915 EP labs OUS

Data source: MarketWatch Global Electrophysiology Device Market Could Exceed $12.2 Billion By 2026. Definitive Healthcare, U.S. News & World Report, Newsweek, and BioSig estimates

Presenting the PURE EP™ Platform

Poised to disrupt the field of electrophysiology, PURE EP™ delivers unprecedented intracardiac signal purity that pushes the boundaries of cardiac arrhythmia identification.

PURE EP™ offers one-of-a-kind algorithms, configurable features, and novel applications not found on any other platform—and there's more in the pipeline.

Saving procedural time and improving workflow efficiency, PURE EP™ eliminates unnecessary inefficiencies to support cost savings.

Supporting our clinical profile with data and economic value

Signal Clarity & Relevance[1]

In a multi-center, randomized prospective study, PURE EP™ signals were compared to conventional recording and mapping systems signals:

75% of PURE EP™ signals rated superior in quality

83% of the time, physicians were more confident in differentiating signal components with PURE EP™

73% of the time, PURE EP™ produced superior small, fractionated signals of clinical significance

Improved Workflow, Time & Cost Savings[2]

To determine the difference in procedural times when comparing ablations guided by PURE EP™'s electrocardiogram (EGM) visualization to the conventional system:

PURE EP™ led to a mean procedure time reduction of:

11.3 minutes

Given that the mean cost of operating room time is approximately **$37 per minute**[3], PURE EP™ demonstrated potential cost savings of approximately:

$418.10 per procedure

1. Al-Ahmad A, Knight B, Tzou W, et al. Evaluation of a novel cardiac signal processing system for electrophysiology procedures: the PURE EP 2.0 study. J Cardiovasc Electrophysiol. 2021;32(11):2915-2922. Epub 2021 Oct 1. DOI: 10.1111/jce.15250

2. Gallinghouse, G. Joseph; Natale, Andrea; Al-Ahmad, Amin; Della Roca, Domenico Giovanni; Jones, Sterling; Firmstone, Samantha; Lewen, Jason. (2022). Time of Redo Atrial Fibrillation Ablation Procedures with PURE EP Recording System for ECG/EGM Visualization: A Randomized Study. Paper presented at APHRS 2022 Singapore: The 15th APHRS Scientific Session [PP-069-2-AF (55)]. Identifier: NCT04964440.

3. Chudzik, R., Distel, D., Stoneman, L., Thording, L. Why Hospital Leaders Should Look to Cardiology for Sustained Future Reprocessing Savings. (2018, April 25). Innovative Health. https://blog.innovative-health.com/blog.

Integrating into EP labs for improved efficiency

PURE EP™

PURE EP™ delivers unprecedented clarity of the raw electrical signals of the heart, unburdening physicians from having to parse through interference of outputs from conventional technology–an on-going problem in EP labs.

Accelerating commercialization of the PURE EP™ Platform

* Expected Full market release.

Current footprint



BioSig technologies

BioSig technologies | PUREEP

"Having high-quality, better signals makes a difference in almost every case. Since we installed the system in our lab, the efficiency in which we operate has significantly improved."

~Dhanunjaya DJ Lakkireddy, MD

Kansas City Heart Rhythm Institute, Overland Park, KS

Complex AF Case Study Utilizing a New Standard in Signal Processing

HCA MIDWEST HEALTH OVERLAND PARK REGIONAL MEDICAL CENTER

HCA Healthcare

Led by strong industry experience

Kenneth L. Londoner, MBA
Founder, Chairman, Chief Executive Officer, Director
Endicott Management Partners; J & W Seligman & Co.; Visiting Professor, Columbia University

Gray Fleming
Chief Commercial Officer
St. Jude Medical; Abbott Laboratories

Steve Buhaly
Chief Financial Officer
Qorvo; Longview Fibre; Planar System

John Sieckaus
Chief Operating Officer
St. Jude Medical; Abbott Laboratories

Brenda Castrodad
VP, Human Resources
TissueTech, Inc.; HeartWare Inc.


Maintaining well-protected IP
59
Utility and Design Patents Granted/ Allowed in the Field of Digital Signal Processing
29
Worldwide Fundamental Patents Granted/Allowed
11
Pending Applications in the U.S.
12
Pending Applications in APAC
30
Worldwide Design Patents Granted/Allowed
8
Pending Applications in Europe
As of April 25, 2023. This includes applications/patents exclusively licensed from May Foundation for Medical Education and Research
12

Why BioSig now?

The solution
Solving the critical unmet need for better intracardiac information that may improve success rates of ablation procedures.

Disruptive and novel technology
Our technology saves procedural time and improves workflow efficiency in an environment where the technology has not changed meaningfully in 25+ years.

Substantial and growing global market
Global EP market is growing by 11.2% and expected to reach $16B by 2028.

Strong clinical data pipeline
Published/ongoing clinical studies supporting commercialization.

First customers are industry leaders
World-renowned Medical Centers of Excellence.

Flexible pricing model
Supports recurring revenue and continuous innovation.

Fortune 500 commercial team
Proven track-record of generating sales growth.

Well-protected IP portfolio
59 Worldwide fundamental patents granted/allowed.

*Global Market Insights Inc. March 08, 2022.

Upcoming Events

New Customer announcements*
U.S. product acquisitions and expansion of footprint.

Participation at Heart Rhythm 2023 in New Orleans May 19-21
The largest gathering of heart rhythm professionals from around the world.

Release of Clinical Data May 2023*
Multiple abstracts have been accepted for presentation at Heart Rhythm 2023.

Software rollout Spring 2023, Fall 2023 and 2024*
Commitment to continuous feature innovation.

* Expected.

Key References

PURE EP™
SEE MORE, CLEARLY

Optimizing signals in the EP lab
Amin Al-Ahmad, MD (Cardiac electrophysiologist - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – Great Debates and Updates in EP - March 2022.
Click here to open

Complex AF case study utilizing a new standard in signal processing
Dhanunjay Lakkireddy, MD (Executive Medical Director, Kansas City Heart Rhythm Institute, Overland Park, KS - USA) – January 2022 - 27th Annual International AF Symposium
Click here to open

Incorporating advanced intracardiac signal information into the clinical workflow
G. Joseph Gallinghouse, MD (Texas Cardiac Arrhythmia Institute, - Austin, TX – USA) – December 2021 - Click here to open

PURE EP™ - from clinical data to clinical applications
Wendy Tzou, MD (University of Colorado Denver, CO.), Andrea Natale, MD and Amin Al-Ahmad, MD (Cardiac electrophysiologists - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – Live Roundtable Webinar – Nov. 2021.
Click here to open

Evaluation of a novel cardiac signal processing system for electrophysiology procedures: The PURE EP 2.0 Study - Al-Ahmad A, Knight B, Tzou W, et al. - J Cardiovasc Electrophysiol. 2021;32(11):2915-2922. Epub 2021 Oct 1. doi: 10.1111/jce.15250.
Click here to open

PURE EP™ - a new standard in signal processing
Amin Al-Ahmad, MD (Cardiac electrophysiologist - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – KC HRS 2021 - August 2021.
Click here to open

From clinical data to clinical applications
Christopher McLeod, MB, ChB (Cardiac electrophysiologist – Mayo Clinic - Jacksonville, FL – USA) – HRS 2021 – Non-CME Satellite Symposium - July 2021 - Click here to open

The evolution of intracardiac signal acquisition and processing in today's EP lab environment - Interview with Amin Al-Ahmad, MD (Cardiac electrophysiologist - St. David's Medical Center - Texas Cardiac Arrhythmia Institute, Austin, TX – USA) – Great Debates & Updates in Electrophysiology - April 2021. - Click here to open

Improved intracardiac signal visualization during cryo and RF procedures
Deepak Gaba, MD (Cardiac electrophysiologist – Memorial Hospital, South Bend, IN – USA) - April 2021, shares his views on how the PURE EP™ System can help be more efficient and how high-fidelity signals can improve clinical outcomes - Click here to open

Benefits of the PURE EP™ System in identifying and interpreting low amplitude signals
G. Joseph Gallinghouse, MD (Texas Cardiac Arrhythmia Institute, - Austin, TX – USA) – January 2021 - 26th International Annual AF Symposium.
Hyperlink to access resources: Click here to open

Further optimizing electrogram signal quality in the EP lab
Bradley P. Knight, MD, FACC, FHRS (Professor of Medicine and Director of EP - Northwestern University, Chicago, IL - USA) – January 2021 - Click here to open\

Advanced signal acquisition help drive procedural efficiency and efficacy
Raffaele Corbisiero, MD, EPS and Pedram Kazemian, MD (Deborah Heat and Lung Center, Browns Mills, New Jersey – USA) EP Lab Digest – December 2020 - Click here to open

VT in NICM by Pasquale Santangeli, MD, PhD - University of Pennsylvania Health System, Philadelphia, PA – USA – November 2020
Hyperlink to access resources: Click here to open

PURE EP case review on how high-fidelity intracardiac signals can help visualize conduction pathways faster - Andrea Natale, MD, FACC - Austin, TX – USA – September 2020 - Click here to open

ESC 2020: A novel cardiac signal processing system for electrophysiology procedures: early insights from the pure ep 2.0 study - Click here to open

Cardiac signal acquisition and clinical considerations for accurate interpretation
Samuel J. Asirvatham, MD (Mayo Clinic, Rochester, Minnesota, USA) and K. L. Venkatachalam, BSEE, M.D. (Mayo Clinic, Jacksonville, FL, USA) - HRS Science 2020 – June 12, 2020.
Click here to open

Cardiac signal acquisition and clinical implications of applying filters
Samuel J. Asirvatham, MD (Mayo Clinic, Rochester, Minnesota, USA) and K. L. Venkatachalam, BSEE, M.D. (Mayo Clinic, Jacksonville, FL, USA) - HRS Science 2020 – July 1, 2020
Click here to open

PURE EP™ is addressing critical unmet needs - frequency bandwidth and linear signal acquisition
Dr Venkatachalam's presentation (Mayo Clinic, Jacksonville, FL - USA) – May 2020 -Stanford Biodesign New Arrhythmia Technologies Retreat - Click here to open

Shaping the future of EP through advanced signal processing and analysis
Andrea Natale, MD, FACC (St David's Medical Center, Austin, TX – USA) and Matthew Dare, CEPS – April 2020 - Click here to open

Contact us

Andy Ballou
VP of Investor Relations
aballou@biosigtech.com
203-409-5444, x133

BioSig Technologies, Inc.
55 Greens Farms Road
Westport, CT 06880

www.biosig.com

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical technology company focused on deciphering the body's electrical signals, starting with heart rhythms. By leveraging a first-of-its-kind combination of hardware and software, BioSig delivers unprecedented cardiac signal clarity, ending the reliance on *mixed signals* and *reading between the lines.* The Company operates within the rapidly growing electrophysiology (EP) marketplace—a market projected to reach $16B by 2028 with an 11.2% growth rate.*

BioSig's first product, the PURE EP™ Platform, is an FDA 510(k) cleared non-invasive class II device, that removes the unnecessary distractions, noise, and signal interruptions inherent in traditional approaches to capturing cardiac signals—preserving access to the full-spectrum of raw signal data and delivering clear actionable insights that can be explored for highly-tailored, efficient procedures in the treatment of arrhythmias.

The PURE EP™ Platform is already an integral part of many well-respected healthcare systems, including Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute.

BioSig Technologies, Inc.
55 Greens Farms Road Westport, CT 06680
www.biosigtech.com
info@biosigtech.com

Kenneth L. Londoner
CEO, Co-Founder, Chairman
BioSig Technologies, Inc.
Phone: (203) 409-5444, x133
klondoner@biosigtech.com

Andrew Ballou
Vice President, Investor Relations
BioSig Technologies, Inc.
Phone: (203) 409-5444, x133
aballou@biosigtech.com

*Global Market Insights Inc. March 08, 2022.

KEY GROWTH DRIVERS

Advanced Technology

- While the field of cardiology has advanced in innumerable ways, platforms for capturing cardiac signaling have not kept pace. BioSig is solving the critical unmet need for delivering better cardiac signaling information that can potentially help improve success rates of ablation procedures, which are fast becoming first-line procedures to treat arrhythmias.
- The PURE EP™ Platform combines noise-dampening physical hardware with one-of-a-kind algorithms and customizable software features to eliminate distortion and provide vital data analysis and pure cardiac signals that allow for enhanced evaluation and confidence in the treatment of arrhythmias.

Market Opportunity

- The global electrophysiology market is expected to exceed US $16B by 2028 and is growing at a compound annual growth rate (CAGR) of 11.2%.

KOL Support

- The PURE EP™ Platform is in use by many of the nation's leading medical centers and physicians, including Dr. Andrea Natale and Dr. G. Joseph Gallinghouse of Texas Cardiac Arrhythmia Institute; Dr. Dhanunjaya “DJ” Lakkireddy of Kansas City Heart Rhythm Institute, and Oussama Wazni, MD of Cleveland Clinic
- The Company achieved proof of concept validation through UCLA and has performed numerous preclinical and clinical studies at leading Medical Centers of Excellence. In 2017, the Company inked a 10-year strategic collaboration with Mayo Clinic. More recently, the Company signed a Master Research Agreement with Cleveland Clinic to explore expanded applications for the PURE EP™ Platform.

RECENT HIGHLIGHTS

- Signed Purchase Agreement with Bellin Health in Green Bay, Wisconsin
- Signed Purchase Agreement with San Antonio Methodist Hospital
- Signed Purchase Agreement with Kansas City Rhythm Institute at Overland Park Medical Center
- PURE EP™ highlighted in a peer-reviewed case report (JAFIB- EP)
- Signed Master Agreement with Hospital Corporation of America (HCA)
- Announced Multi-System Evaluation Agreement with Cleveland Clinic
- Surpassed 3,000 procedures
- 59 allowed/issued design and utility patents
- Clinical data acquired by PURE EP™ published in the Journal of Cardiovascular Electrophysiology
- Selected Plexus Corp. as its manufacturing partner

THE PURE EP™ PLATFORM

A unique combination of proprietary hardware and software, The PURE EP™ Platform removes unnecessary distractions to preserve the value of cardiac signals and delivers clear, actionable insights for today's electrophysiologist. PURE EP™ is demonstrating impact on hospital profitability through innovative feature designs not found in any other platform.

- Reduce EP lab noise and artifacts
- Deliver clean, superior intracardiac signal visualization
- Offer customizable, advanced software modularity
- Enhance clinical workflow and increase throughput
- Empower physicians with actionable insights
- Improve clinical decision-making

The company's subscription model supports operational expenditure goals by optimizing case-by-case and day-to-day department expenses, removing the burden of ownership and maintenance. With a comprehensive suite of tools and software upgrades, the PURE EP™ Platform can deliver the latest developments in electrophysiology to physicians as they emerge, with the flexibility to add enhancements as desired.

A GROWING GLOBAL MARKET

The Cardiac Arrhythmia Epidemic:
14.4M Americans suffer from cardiac arrhythmias.

Two of the most prevalent, complex and potentially deadly types of arrhythmias today are Atrial Fibrillation (AF) and Ventricular Tachycardia (VT).

- AF is the most common arrhythmia affecting 33.5 million people worldwide, with as many as 6.1 million people in the U.S. now and expected 8-12 million by 2050. AF increases the risk of stroke 4x to 5x and contributes to ~750,000 hospitalizations per year. The direct cost of AF is approximately $6B annually; adding other indirect costs brings AF total cost to $26B.
- Ventricular arrhythmias account for approximately 300,000 sudden deaths per year in the United States alone.

Catheter ablation is fast becoming a first-line therapy, driving demand for improved technologies.

- Global Ablation Procedure Growth: 8.4% growth rate, from 973,220 in 2017 to 1.45 projected million in 2022.
- Complex Ablation Procedures: 440,629 in 2017 to 830,390 in 2022; 13.5% projected growth rate.
- Estimated 3,425 EP labs in US
- Estimated 3,915 EP labs OUS

INVESTMENT HIGHLIGHTS

- Proven management team and independent Board of Directors
- Substantial and growing market
- Strong clinical data supports commercialization
- Technology solves a critical unmet need, saves procedural time, and improves workflow efficiency
- Flexible pricing model supports recurring revenue and continuous innovation
- First customers are industry leaders
- IP Strategy led by Sherpa Technology and Sterne Kessler Goldstein & Fox—59 allowed/issues patents
- Significant Insider Ownership
- National purchasing agreement with HCA, Inc.
- 10-year strategic collaboration with Mayo Clinic

PROVEN TEAM

BioSig is led by a proven management team with significant inside ownership. BioSig has brought together leading physicians, executives and engineering experts from leading medical centers of excellence, healthcare programs, Fortune 500 Companies and elite educational institutions for its Advisory Board, including Mayo Clinic, Mount Sinai Medical Center, UCLA, Johnson & Johnson, Nasdaq and Prudential Securities.

MANAGEMENT AND PAST EXPERIENCE	Kenneth L. Londoner, MBA *Founder, Chairman, Chief Executive Officer, Director* Endicott Management Partners; J & W Seligman & Co., Visiting Professor, Columbia University	Steve Buhaly *Chief Financial Officer* Qorvo; Longview Fibre; Planar Systems
	Gray Fleming *Chief Commercial Officer* St. Jude Medical; Abbott Laboratories	John Sieckhaus *Chief Operating Officer* St. Jude Medical; Abbott Laboratories
	Andrew Ballou *VP, Investor Relations* Janney Montgomery Scott LLC., RBC Capital Markets	Brenda Castrodad *VP, Human Resources* TisueTech, Inc., HeartWare Inc.
	Katie Freshwater *VP, Marketing* Cardinal Health, Medtronic, Kimberly-Clark Healthcare	Zachary Koch *CCDS, CEPS, Clinical Director* Abbott, St. Jude Medical

DIRECTORS	Donald E. Foley *Director* Former CEO & Chair: Wilmington Trust; Sr VP, Treas & Dir: ITT Corp; Asst Treas: International Paper Co	Patrick J. Gallagher, MBA *Director* Mg Dir: Laidlaw & Co.; Kinex Pharmaceuticals; Director: Cingulate Therapeutics, BDR Research Group, GC Capital Partners, Kidder Peabody
	David Weild IV, MBA *Director* Current Chairman & CEO; Weild & Co.; Former Vice Chairman: NASDAQ; Former Head of Corporate Finance & Equity Markets: Prudential Securities	Frederick D. Hrkac *Director* 30+ years of industry experience including Europe, Middle East & Africa President of Boston Scientific; Executive: Johnson & Johnson, Biosense Webster
	James Klein *Director* Former President of Infrastructure and Defense Products, Qorvo, where he was focused on bringing innovative RF technology to the medical testing market	James J. Barry *Director* Principal Owner; Convergent Biomedical Group LLC; former President and CEO; InspireMD, Inc.; former SVP of Corporate Technology at Boston Scientific

ANALYST COVERAGE	Laidlaw & Co (UK) Ltd., Taglich Brothers, Ascendiant Capital Markets, Trickle Research

BioSig Forward-Looking Statements: Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, regulatory approvals, competition and marketplace demand. More information, and BioSig risk factors, are set forth in its filings with the SEC. BioSig assumes no obligation to publicly update or revise its forward-looking statements. Data Sources: 2018 MD&D report, Worldwide Epidemiology of Atrial Fibrillation in the journal Circulation, 2013; CDC Fact Sheet on Atrial Fibrillation; American Heart Association; Ventricular Tachycardia in Medscape, December 2017; “Healthcare Costs Drop Sharply after Successful Ablation,” Marlene Busko, Medscape, May 4, 2016 , and Biolelectronic Medicine 2019-2029. IDTechEx Research. *As reported in the 09/30/21 form 10Q filed on November 15th, 2021.